MX2019003470A - Composicion farmaceutica y metodo para el tratamiento de la enfermedad del higado graso no alcoholico. - Google Patents
Composicion farmaceutica y metodo para el tratamiento de la enfermedad del higado graso no alcoholico.Info
- Publication number
- MX2019003470A MX2019003470A MX2019003470A MX2019003470A MX2019003470A MX 2019003470 A MX2019003470 A MX 2019003470A MX 2019003470 A MX2019003470 A MX 2019003470A MX 2019003470 A MX2019003470 A MX 2019003470A MX 2019003470 A MX2019003470 A MX 2019003470A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- pharmaceutical composition
- liver disease
- fatty liver
- alcoholic fatty
- Prior art date
Links
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- -1 1,4-benzoxazine compound Chemical class 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invencion proporciona una composicion farmaceutica para la profilaxis y el tratamiento de la EHGNA que comprende como un ingrediente activo un compuesto de 1,4- benzoxazina representado por la formula (I): o una sal farmaceuticamente aceptable del mismo, y un vehiculo farmaceuticamente aceptable, asi como un metodo para la profilaxis y el tratamiento de la EHGNA el cual comprende administrar una cantidad terapeuticamente eficaz del compuesto de 1,4-benzoxazina mencionado anteriormente representado por la formula (I) y demas a un paciente en necesidad del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662400200P | 2016-09-27 | 2016-09-27 | |
| PCT/JP2017/034654 WO2018062134A1 (en) | 2016-09-27 | 2017-09-26 | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019003470A true MX2019003470A (es) | 2019-08-29 |
Family
ID=60083378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019003470A MX2019003470A (es) | 2016-09-27 | 2017-09-26 | Composicion farmaceutica y metodo para el tratamiento de la enfermedad del higado graso no alcoholico. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11285160B2 (es) |
| EP (1) | EP3518936B1 (es) |
| JP (1) | JP6980008B2 (es) |
| KR (1) | KR20190061027A (es) |
| CN (2) | CN114984021A (es) |
| AU (1) | AU2017338161A1 (es) |
| BR (1) | BR112019005456A2 (es) |
| CA (1) | CA3038247A1 (es) |
| CO (1) | CO2019004004A2 (es) |
| ES (1) | ES2840079T3 (es) |
| IL (1) | IL265292A (es) |
| MX (1) | MX2019003470A (es) |
| PH (1) | PH12019500618A1 (es) |
| RU (1) | RU2019112148A (es) |
| TW (1) | TW201817425A (es) |
| WO (1) | WO2018062134A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102162921B1 (ko) * | 2018-11-28 | 2020-10-07 | 건양대학교 산학협력단 | 니페디핀 함유 나노입자를 포함하는 지방간 질환 및 인슐린 저항성 예방 또는 치료용 조성물 |
| AR117988A1 (es) | 2019-02-05 | 2021-09-08 | Mitsubishi Tanabe Pharma Corp | Medicamento para profilaxis o tratamiento para la fibrosis pulmonar |
| US20230015691A1 (en) * | 2019-11-26 | 2023-01-19 | Mitsubishi Tanabe Pharma Corporation | Prophylactic or therapeutic agent for non-alcoholic steatohepatitis in humans |
| WO2023101441A1 (ko) * | 2021-11-30 | 2023-06-08 | 에스케이케미칼 주식회사 | 마이크로조말 트리글리세라이드 전달 단백질 억제제의 섬유화 질환 치료 용도 |
| CN117379414A (zh) * | 2023-11-09 | 2024-01-12 | 中国人民解放军陆军军医大学第一附属医院 | 盐酸决奈达隆在制备治疗非酒精性脂肪性肝病和胆汁淤积性肝病的药物中的应用 |
| CN118766941B (zh) * | 2024-08-14 | 2025-11-14 | 中国药科大学 | 洛美他派及其组合物在制备治疗肝纤维化的药物中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000064478A1 (en) * | 1999-04-27 | 2000-11-02 | Mitsubishi Pharma Corporation | Preventives/remedies for liver diseases |
| TWI385161B (zh) | 2006-02-02 | 2013-02-11 | Mitsubishi Tanabe Pharma Corp | 含氮雜雙環化合物 |
| ES2368598T3 (es) * | 2006-02-02 | 2011-11-18 | Mitsubishi Tanabe Pharma Corporation | Benzoxacinas y compuestos heterobicíclicos que contienen nitrógeno relacionados útiles como agentes moduladores de receptores de mineralocorticoides. |
| US8258131B2 (en) * | 2007-08-01 | 2012-09-04 | Mitsubishi Tanabe Pharma Corporation | Fused bicyclic compound |
| JP5173653B2 (ja) * | 2007-08-01 | 2013-04-03 | 田辺三菱製薬株式会社 | 医薬組成物 |
| WO2011118976A2 (en) * | 2010-03-24 | 2011-09-29 | Dong-A Pharm. Co., Ltd. | Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same |
| EP2883870B8 (en) * | 2012-08-08 | 2019-01-23 | Mitsubishi Tanabe Pharma Corporation | Method for producing 1,4-benzoxazine compound |
-
2017
- 2017-09-26 BR BR112019005456A patent/BR112019005456A2/pt not_active IP Right Cessation
- 2017-09-26 CA CA3038247A patent/CA3038247A1/en not_active Abandoned
- 2017-09-26 CN CN202210632897.4A patent/CN114984021A/zh active Pending
- 2017-09-26 TW TW106132944A patent/TW201817425A/zh unknown
- 2017-09-26 CN CN201780057969.4A patent/CN109789147B/zh not_active Expired - Fee Related
- 2017-09-26 WO PCT/JP2017/034654 patent/WO2018062134A1/en not_active Ceased
- 2017-09-26 JP JP2019516546A patent/JP6980008B2/ja not_active Expired - Fee Related
- 2017-09-26 ES ES17784023T patent/ES2840079T3/es active Active
- 2017-09-26 US US16/336,667 patent/US11285160B2/en active Active
- 2017-09-26 RU RU2019112148A patent/RU2019112148A/ru not_active Application Discontinuation
- 2017-09-26 EP EP17784023.8A patent/EP3518936B1/en not_active Not-in-force
- 2017-09-26 KR KR1020197011752A patent/KR20190061027A/ko not_active Ceased
- 2017-09-26 MX MX2019003470A patent/MX2019003470A/es unknown
- 2017-09-26 AU AU2017338161A patent/AU2017338161A1/en not_active Abandoned
-
2019
- 2019-03-11 IL IL265292A patent/IL265292A/en unknown
- 2019-03-21 PH PH12019500618A patent/PH12019500618A1/en unknown
- 2019-04-23 CO CONC2019/0004004A patent/CO2019004004A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019529477A (ja) | 2019-10-17 |
| RU2019112148A (ru) | 2020-10-29 |
| KR20190061027A (ko) | 2019-06-04 |
| WO2018062134A1 (en) | 2018-04-05 |
| CN114984021A (zh) | 2022-09-02 |
| TW201817425A (zh) | 2018-05-16 |
| IL265292A (en) | 2019-05-30 |
| US20210290627A1 (en) | 2021-09-23 |
| CO2019004004A2 (es) | 2019-07-31 |
| CA3038247A1 (en) | 2018-04-05 |
| ES2840079T3 (es) | 2021-07-06 |
| BR112019005456A2 (pt) | 2019-06-04 |
| US11285160B2 (en) | 2022-03-29 |
| AU2017338161A1 (en) | 2019-04-18 |
| EP3518936A1 (en) | 2019-08-07 |
| CN109789147A (zh) | 2019-05-21 |
| EP3518936B1 (en) | 2020-11-18 |
| PH12019500618A1 (en) | 2019-11-18 |
| JP6980008B2 (ja) | 2021-12-15 |
| RU2019112148A3 (es) | 2021-01-15 |
| CN109789147B (zh) | 2022-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| MX2021004431A (es) | Procesos novedosos. | |
| PH12020550341A1 (en) | Niraparib formulations | |
| MX2016000307A (es) | Farmaco para el tratamiento de la esteatosis hepatica no alcoholica. | |
| MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| JOP20180071B1 (ar) | استخدام مشتقات أمينو ألكيل بنزوثيازبين | |
| MX2022004451A (es) | Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1. | |
| MX2021010106A (es) | Inhibidores de la via de respuesta al estres integrada. | |
| BR112013021566A2 (pt) | composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula | |
| MY197171A (en) | Compounds and methods for the treatment of parasitic diseases | |
| PH12014500065A1 (en) | A new therapeutical composition containing apomorphine as active ingredient | |
| SG10201907291QA (en) | Monomethylfumarate prodrug compositions | |
| MX381440B (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
| PH12015501945B1 (en) | Formulations of organic compounds | |
| JOP20190086A1 (ar) | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب | |
| TN2016000491A1 (en) | Carboxamide derivatives. | |
| EA201891319A1 (ru) | Соединения алкилдигидрохинолинсульфонамида | |
| MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
| PH12020551117A1 (en) | Compositions for preventing or treating uveitis | |
| CO2022008616A2 (es) | Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma | |
| MX2019006942A (es) | Agonistas de receptores de oxitocina no peptidicos. | |
| MX2019014321A (es) | Compuestos biciclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias. | |
| MX2022006052A (es) | Inhibidores de la caspasa 6 y usos de los mismos. | |
| MX386902B (es) | Metodos para el tratamiento de trastornos cardiovasculares. |